论文部分内容阅读
Purpose: Oncogenic KIT or PDGFRA tyrosine kinase mutations are compelling therapeutic targets in most gastrointestinal stromal tumors(GISTs),and the KIT/PDGFRA inhibitor,imatinib,is therefore standard of care for patients with metastatic GIST.